Eli Lilly Navigates Turbulent Waters Amid mRNA Funding Cuts and Biotech Layoffs
Eli Lilly faces hurdles as the U.S. government slashes mRNA funding, leading to biotech sector layoffs including at Tune Therapeutics. The shift in funding priorities away from mRNA research, due to government policy changes, impacts the wider mRNA research community and major players like Eli Lilly. Despite successes in other drug areas, Eli Lilly must navigate setbacks in mRNA-dependent projects.
Aug 9